|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2010-4-2
|
|
pubmed:abstractText |
Nuclear receptor coactivator expression and activity may partly explain the complex agonist/antagonist effects of tamoxifen at clinical level. In a preoperative trial, dose reduction from 20 to 1 mg tamoxifen was associated with retained antiproliferative effect on breast cancer. Here, we assessed the gene expression of the steroid receptor coactivators SRC-1, SRC-2/transcription intermediary factor 2, and SRC-3/amplified in breast cancer 1 (AIB1) and the growth factor receptor HER-2/neu under three tamoxifen dose regimens.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BonanniBernardoB,
pubmed-author:De CensiAndreaA,
pubmed-author:DeCensiAndreaA,
pubmed-author:GandiniSaraS,
pubmed-author:Guerrieri-GonzagaAlianaA,
pubmed-author:Haugan MoiLine LLL,
pubmed-author:Hauglid FlågengMarianneM,
pubmed-author:LazzeroniMatteoM,
pubmed-author:LienErnst AEA,
pubmed-author:MellgrenGunnarG,
pubmed-author:ToxopeusM DMD
|
|
pubmed:copyrightInfo |
Copyright 2010 AACR.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2176-86
|
|
pubmed:dateRevised |
2010-10-20
|
|
pubmed:meshHeading |
pubmed-meshheading:20332317-Adult,
pubmed-meshheading:20332317-Aged,
pubmed-meshheading:20332317-Antineoplastic Agents,
pubmed-meshheading:20332317-Breast,
pubmed-meshheading:20332317-Breast Neoplasms,
pubmed-meshheading:20332317-Carcinoma,
pubmed-meshheading:20332317-Dose-Response Relationship, Drug,
pubmed-meshheading:20332317-Double-Blind Method,
pubmed-meshheading:20332317-Drug Resistance, Neoplasm,
pubmed-meshheading:20332317-Female,
pubmed-meshheading:20332317-Follow-Up Studies,
pubmed-meshheading:20332317-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:20332317-Humans,
pubmed-meshheading:20332317-Middle Aged,
pubmed-meshheading:20332317-Nuclear Receptor Coactivator 3,
pubmed-meshheading:20332317-Randomized Controlled Trials as Topic,
pubmed-meshheading:20332317-Tamoxifen
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue.
|
|
pubmed:affiliation |
Institute of Medicine, University of Bergen, Hormone Laboratory, Haukeland University Hospital, Bergen, Norway.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
